NewcelX Ltd. Ordinary Shares (NCEL) is a publicly traded the market company. As of May 21, 2026, NCEL trades at $2.91 with a market cap of $16.74M and a P/E ratio of 0.00. NCEL moved +0.00% today. Year to date, NCEL is +45.74%; over the trailing twelve months it is flat. Its 52-week range spans $1.83 to $7.64. Rallies surfaces NCEL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
NewcelX Secures $1.35M Private Placement at 30% Premium to Advance NCEL-101: NewcelX raised $1.35 million in a private placement at $2.75 per share, 30% above the March 31 close, selling 490,907 common shares and warrants for 687,270 shares exercisable at $3.025. Proceeds, plus a $25 million equity line, will fund advancement of its lead NCEL-101 Type 1 Diabetes program.
| Metric | Value |
|---|---|
| Price | $2.91 |
| Market Cap | $16.74M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.64 |
| 52-Week Low | $1.83 |
| Volume | 17 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
NCEL analyst coverage data. Average price target: $0.00.